Kyverna Therapeutics Appoints New Chief Medical Officer
Ticker: KYTX · Form: 8-K · Filed: Sep 16, 2024 · CIK: 1994702
Sentiment: neutral
Topics: executive-appointment, personnel
TL;DR
Kyverna names Dr. Ybarra, ex-Gilead, as CMO to drive cell therapy development.
AI Summary
Kyverna Therapeutics, Inc. announced on September 13, 2024, the appointment of Dr. Michael J. Ybarra as Chief Medical Officer. Dr. Ybarra brings extensive experience in clinical development and regulatory affairs from his previous roles at companies like Gilead Sciences and Bristol Myers Squibb. This appointment is part of Kyverna's ongoing efforts to advance its pipeline of cell therapies for autoimmune diseases.
Why It Matters
The appointment of a seasoned Chief Medical Officer like Dr. Ybarra signals Kyverna's commitment to advancing its clinical programs and potentially strengthens investor confidence in the company's leadership and strategic direction.
Risk Assessment
Risk Level: medium — The appointment of a new executive is a significant event, but the filing does not contain information about the company's financial health or major strategic shifts, placing it at a medium risk level.
Key Players & Entities
- Kyverna Therapeutics, Inc. (company) — Registrant
- Dr. Michael J. Ybarra (person) — Appointed Chief Medical Officer
- Gilead Sciences (company) — Previous employer of Dr. Ybarra
- Bristol Myers Squibb (company) — Previous employer of Dr. Ybarra
- September 13, 2024 (date) — Date of earliest event reported
FAQ
Who has been appointed as the new Chief Medical Officer of Kyverna Therapeutics?
Dr. Michael J. Ybarra has been appointed as the new Chief Medical Officer of Kyverna Therapeutics.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on September 13, 2024.
What is Kyverna Therapeutics, Inc.'s state of incorporation?
Kyverna Therapeutics, Inc. is incorporated in Delaware.
What is the business address of Kyverna Therapeutics?
The business address of Kyverna Therapeutics is 5980 Horton St., STE 550, Emeryville, California 94608.
What is the SIC code for Kyverna Therapeutics?
The SIC code for Kyverna Therapeutics is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Stats: 2,871 words · 11 min read · ~10 pages · Grade level 10.9 · Accepted 2024-09-16 08:05:08
Key Financial Figures
- $0.00001 — ch registered Common Stock, par value $0.00001 per share KYTX The Nasdaq Stock Mar
- $625,000 — dle's initial annualized salary will be $625,000, and he will be paid a one-time bonus o
- $650,000 — and he will be paid a one-time bonus of $650,000, less applicable withholdings (the "Sig
- $150,000 — be entitled to be reimbursed for up to $150,000 of relocation/moving expenses. Mr. Bidd
- $45,833.33 — vide Dr. Maag with a monthly payment of $45,833.33 (payable no later than the last day of
- $550,000 — then (i) the Company shall pay Dr. Maag $550,000, less all applicable withholdings and d
- $40,000 — eive cash compensation in the amount of $40,000 per year for her service on the Board,
- $350,000 — e Company's common stock as is equal to $350,000, divided by the closing price of the Co
Filing Documents
- ea0214607-8k_kyverna.htm (8-K) — 59KB
- ea021460701ex10-1_kyverna.htm (EX-10.1) — 92KB
- ea021460701ex10-2_kyverna.htm (EX-10.2) — 47KB
- ea021460701ex10-3_kyverna.htm (EX-10.3) — 146KB
- ea021460701ex99-1_kyverna.htm (EX-99.1) — 16KB
- ex10-1_001.jpg (GRAPHIC) — 3KB
- ex10-2_001.jpg (GRAPHIC) — 8KB
- 0001213900-24-078736.txt ( ) — 629KB
- kytx-20240913.xsd (EX-101.SCH) — 3KB
- kytx-20240913_lab.xml (EX-101.LAB) — 33KB
- kytx-20240913_pre.xml (EX-101.PRE) — 22KB
- ea0214607-8k_kyverna_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits. Number Description 10.1 Employment Offer Letter, dated September 14, 2024, between Kyverna Therapeutics, Inc. and Warner Biddle. 10.2 Separation and General Release Agreement, dated September 13, 2024, between Kyverna Therapeutics, Inc. and Peter Maag, Ph.D . 10.3 Kyverna Therapeutics, Inc. 2024 Inducement Equity Incentive Plan. 99.1 Press Release, dated September 16, 2024 . 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 4
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KYVERNA THERAPEUTICS, INC. Date: September 16, 2024 By: /s/ Ian Clark Name: Ian Clark Title: Chairperson of the Board 5